LCTX (STOCKS)
Lineage Cell Therapeutics, Inc.
$1.249900
-0.020100 (-1.58%)
Prev close: $1.270000
Company Information
- Exchange
- XASE
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Brian M. Culley
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $311.60M
- Employees
- 77
- P/E (TTM)
- -4.42
- P/B (TTM)
- 5.88
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
3
Strong Buy
8
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.03 | $-0.02 | -0.0096 | -47.06% |
|
Mar 2025 (Q4)
|
$0.00 | $-0.05 | +0.0527 | +100.00% |
|
Sep 2025 (Q3)
|
$-0.13 | $-0.03 | -0.1038 | -396.18% |
|
Jun 2025 (Q2)
|
$-0.07 | $-0.03 | -0.0423 | -152.71% |
Financial Statements
| Revenues | $14.78M |
| Benefits Costs and Expenses | $84.07M |
| Costs And Expenses | $52.49M |
| Nonoperating Income/Loss | -$31.59M |
| Operating Expenses | $52.49M |
| Depreciation and Amortization | $723.00K |
| Research and Development | $18.85M |
| Other Operating Expenses | $32.91M |
| Operating Income/Loss | -$37.71M |
| Income/Loss From Continuing Operations After Tax | -$64.01M |
| Income/Loss From Continuing Operations Before Tax | -$69.29M |
| Income Tax Expense/Benefit, Deferred | -$5.28M |
| Net Income/Loss | -$64.01M |
| Net Income/Loss Attributable To Noncontrolling Interest | $193.00K |
| Net Income/Loss Attributable To Parent | -$64.21M |
| Net Income/Loss Available To Common Stockholders, Basic | -$64.21M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.28 |
| Diluted Earnings Per Share | -$0.29 |
| Basic Average Shares | 704,589,000 |
| Diluted Average Shares | 720,735,000 |
| Assets | $109.53M |
| Current Assets | $56.16M |
| Noncurrent Assets | $53.37M |
| Fixed Assets | $2.50M |
| Intangible Assets | $31.70M |
| Other Non-current Assets | $19.17M |
| Liabilities | $56.84M |
| Current Liabilities | $8.15M |
| Accounts Payable | $1.59M |
| Wages | $2.74M |
| Other Current Liabilities | $3.82M |
| Noncurrent Liabilities | $48.69M |
| Equity | $52.70M |
| Equity Attributable To Noncontrolling Interest | -$1.18M |
| Equity Attributable To Parent | $53.88M |
| Liabilities And Equity | $109.53M |
| Net Cash Flow From Operating Activities | -$22.11M |
| Net Cash Flow From Operating Activities, Continuing | -$22.11M |
| Net Cash Flow From Investing Activities | -$17.69M |
| Net Cash Flow From Investing Activities, Continuing | -$17.69M |
| Net Cash Flow From Financing Activities | $27.47M |
| Net Cash Flow From Financing Activities, Continuing | $27.47M |
| Exchange Gains/Losses | $464.00K |
| Net Cash Flow | -$11.87M |
| Net Cash Flow, Continuing | -$12.33M |
| Comprehensive Income/Loss | -$65.30M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $193.00K |
| Comprehensive Income/Loss Attributable To Parent | -$65.50M |
| Other Comprehensive Income/Loss | -$1.29M |